Investment Q&A

Q: I currently just have ABBV in my portfolio so was thinking about adding an Healthcare ETF. You often mention IYH and XLV in your QandA; do you have any others that you would recommend with a higher dividend as I am an income investor who want some growth? IYH has a 3% div on 5i site, but 1% on most other sites - could you explain that? Was also thinking about adding MRK. Can you comment for a longer term hold. Thank you.

Q: Performing very well on a tough overall day, clearly the market is very impressed with VHI's acquisition of Strata Health.

As always, would appreciate your analysis.

Q: My wife feels like she has too big a position in WELL for a relatively small company.

She is thinking of selling of some and buying ISRG or else TMDX during what seems an attractive current dip.

She is fine with risk, so is considering ISRG for its growth more than its stability.

Please give your thoughts on the relative outlook for each of these companies in the mid- to long-term.

Q: The market seems to really like the earnings of ABBV. Got a nice dividend raise too. Where do you see the runway for this is over the next five years?

Jimmy

Q: Which drug companies would you suggest if arriving late to the GLP-1 party? For a 5-10 year hold.
Thanks

Q: Hello 5i Team,

Your thoughts on these 3 names. SRRK & CRNX gave us good returns with the recent run and I intend to replace with IBRX.

Thank you!

Q: Hi,
Few weeks ago I bought a small position in TMDX at $130. As the stock got closer to earnings, I sold some naked puts at $105, collected a nice premium and expecting that if it dropped after earnings, I could pick up some more 20% lower which I'm happy to do. With the larger stock drop after earnings down to $85 now, I'm thinking about my options. I'll most likely be assigned the shares at $105, which expire in 2 weeks.

As you have mentioned in many comments, I think these results are temporary headwinds and long term I'm still bullish. I'm tempted to 1) sell another put at around $70-75 and if the stock drops there, I'm happy to buy more. If it rises, I just keep the premium and reduce my cost base. Or 2) I was thinking I could buy the stock here and sell a covered call at around $95-100? Any other ideas you would implement here if this were you? what would YOU do if this were you? Thank you!

Q: Your thoughts on earnings and outlook please. Thank-you.

Q: According to Portfolio Analytics, my current allocation to Health Care sector is too low. Here are the names of 12 major US pharmaceutical companies. How would you rank them? If possible, please provide a short comment on each of them: Pfizer, Johnson and Johnson, AbbVie, Amgen, Gilead Sciences, Eli Lilly, Merck, Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Abbott, Biogen, Bristol Myers Squibbs. Thank you

Q: Any comments on the company going forward would be appreciated. I have a small position that as of today has jumped up to 4%. I know you don't personalize responses but buy sell or hold? Take some profit?

Q: Hi,

I find the 3 following health stocks interesting: isrg-q, janx-q, wgs-q How would you rate them for strong growth in a period of 3 years and why ? Any other you like better in the sector ? Why ?

Gratefully,

Jacques IDS

Q: Is this company a good prospect to invest in.

Q: I just read the third quarter results. The market reaction is horrible. It looks like its going to drop 30 percent at opening. My issue is I didn't see any red flags. Growth target is on track. The only negative was a drop in gross margin which was explained. Should I buy on the dip once the price stabilizes.

Q: Appreciate your insights please.

Q: Its been flat for 10 years now. Before Paladin Labs took off how long was the stock doing nothing before it was taken out? Are there signs that should monitored that will show things are about to inflect? They keep buying back lots of shares and presumably executing on their strategy.

Q: Could you please comment on ISRG earnings and your opinion on the outlook moving forward?

Thank-you!

Q: Hi,

Can you please confirm the FY24 and FY25 consensus EPS as seen on your Key Ratios company page for WELL. It seems the EPS is forecast to drop approx 40%.... .17 cents vs .12 cents respectively which does not seem very enticing. Although many of the other key ratios do look attractive so I wonder what is keeping this stock from performing better?
I have owned WELL for awhile now (marginally ahead) but my patience is growing thin and was thinking of splitting some of the proceeds (if I sell) towards Vitalhub and/or Kneat (which are both now close to their 52 week highs vs WELL) as part of my small cap health exposure. I took part in a DKAM update yesterday and they have VHI and KSI as part of their top 10 stocks for 2025 and I have followed some of their recommendations for years and done very well.
Just curious what your favourite is of these 3 health stocks. In the past you have suggested all 3 as favourable at various times but I know acquisitions etc can move some stocks ahead of others and all have made recent headlines.

Cheers,
SMc

Q: Is aidx.to worth buying for a small cap portfolio?

Q: Just finished reading both questions and your report on CPH ..... I don't see any resemblance between your report and the current company .... Could you give me the " Cole's Notes " review of the state of the current company ? What's positive in the pipeline ? What's negative ? I see the failure of the nail fungus drug initially dropped the stock $5 but it has recovered since. Does that mean the drug is not dead ? Thanks for your terrific service ..... { any plans to update that report ? }

Q: What are your top three non-tech CDR Stocks to invest for the long-term?